Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: NVS

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off

By Vandana Singh
February 1, 6:47 AM
Novartis AG (NYSE:NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating the consensus of $1.44.…

NVS

Read More
1 minute read
  • Earnings
  • News

Novartis Q4 Core EPS $1.52 Beats $1.44 Estimate, Sales $12.69B Miss $13.13B Estimate

By Benzinga Newsdesk
February 1, 4:23 AM
Novartis (NYSE:NVS) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.44 by 5.56 percent. This is a 8.57 percent increase over earnings of $1.40 per share from the same period

NVS

Read More
1 minute read
  • Economics
  • Macro Economic Events
  • News

World Organization For Animal Health Says Bolivia Reports Outbreaks Of Highly Pathogenic Bird Flu In Poultry

By Happy Mohamed
January 31, 12:52 PM
- Reuters

GNBT

Read More
1 minute read
  • Earnings

A Preview Of Novartis’s Earnings

By Benzinga Insights
January 31, 10:01 AM
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Wednesday, 2023-02-01. Here’s what investors need…

NVS

Read More
5 minute read
  • Earnings
  • News
  • Previews
  • Small Cap
  • Tech
  • Top Stories
  • Trading Ideas

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch

By Shanthi Rexaline
January 29, 6:25 PM
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

AAPL

Read More
1 minute read
  • News

Novartis Warns U.S. Plan To Curb Drug Prices Could Hit Key Research

By Benzinga Newsdesk
January 20, 10:31 AM
- Reuters

NVS

Read More
1 minute read
  • Cannabis
  • Contracts
  • Global
  • Guidance
  • Management
  • Markets
  • News
  • Penny Stocks
  • Psychedelics
  • Top Stories

Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects

By Lara Goldstein
January 19, 3:57 PM
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.

BSX

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Price Target
  • Reiteration

Analyst Views Novo Nordisk’s Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly’s Tirzepatide

By Vandana Singh
January 19, 1:19 PM
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023. 

AMGN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • M&A
  • News

Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units

By Vandana Singh
January 10, 10:41 AM
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology.

NVS

Read More
1 minute read
  • News
  • Rumors
  • Trading Ideas

Traders Circulate Post Suggesting Novartis AG ‘Misses On 2nd Interim For NATALEE Trial. Not A Good Sign For Differentiation Vs Abema’

By Benzinga Newsdesk
January 9, 12:34 PM
https://twitter.com/pharmacreep/status/1612487217800167424

NVS

Posts navigation

1 2 … 29 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service